Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation
- PMID: 14697745
- DOI: 10.1016/j.clim.2003.08.002
Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation
Abstract
Chronic granulomatous disease (CGD) is an inherited immunodeficiency resulting from defects in the multienzyme complex NADPH-oxidase (phagozyte oxidase, phox), which normally produces microbicidal reactive oxygen metabolites (ROM). The reason for our patient's CGD was unusual, as revealed by the following in vitro findings in neutrophils and EBV-transformed B-cells: lack of flavocytochrome b(558) expression, restoration of significant ROM production after transduction with gp91-phox cDNA by a retrovirus vector, an 879G-->A, Trp289-->Stop mutation in one X chromosomal gp91-phox allele, a one-sided paternal X chromosome inactivation, as shown by a lyonization assay at the HUMARA locus, and the result of a dihydrorhodamine 123 flow cytometry assay revealing consistently that 1 in 2500 neutrophils produced ROM at normal levels. Our conclusion: A presumed autosomal form of CGD has been excluded. Instead, a spontaneous mutation in gp91-phox coinciding with an extreme X chromosome inactivation ratio resulted in X-linked CGD in this young woman.
Similar articles
-
Missense mutations in the gp91-phox gene encoding cytochrome b558 in patients with cytochrome b positive and negative X-linked chronic granulomatous disease.Blood. 1999 Mar 15;93(6):2098-104. Blood. 1999. PMID: 10068684
-
Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase.J Biol Chem. 1998 Oct 23;273(43):27879-86. doi: 10.1074/jbc.273.43.27879. J Biol Chem. 1998. PMID: 9774399
-
An in-frame triplet deletion within the gp91-phox gene in an adult X-linked chronic granulomatous disease patient with residual NADPH-oxidase activity.Eur J Haematol. 1997 Feb;58(2):78-85. doi: 10.1111/j.1600-0609.1997.tb00928.x. Eur J Haematol. 1997. PMID: 9111587
-
Hematologically important mutations: X-linked chronic granulomatous disease (third update).Blood Cells Mol Dis. 2010 Oct 15;45(3):246-65. doi: 10.1016/j.bcmd.2010.07.012. Epub 2010 Aug 21. Blood Cells Mol Dis. 2010. PMID: 20729109 Free PMC article. Review.
-
[Molecular aspects of chronic granulomatous disease. "the NADPH oxidase complex"].Bull Acad Natl Med. 2007 Feb;191(2):377-90; discussion 390-2. Bull Acad Natl Med. 2007. PMID: 17969555 Review. French.
Cited by
-
ConteXt of change--X inactivation and disease.EMBO Mol Med. 2010 Jan;2(1):6-15. doi: 10.1002/emmm.200900053. EMBO Mol Med. 2010. PMID: 20043281 Free PMC article.
-
Residual NADPH oxidase and survival in chronic granulomatous disease.N Engl J Med. 2010 Dec 30;363(27):2600-10. doi: 10.1056/NEJMoa1007097. N Engl J Med. 2010. PMID: 21190454 Free PMC article.
-
Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease.Pediatric Health Med Ther. 2020 Jul 22;11:257-268. doi: 10.2147/PHMT.S254253. eCollection 2020. Pediatric Health Med Ther. 2020. PMID: 32801991 Free PMC article. Review.
-
Considerations in the Diagnosis of Chronic Granulomatous Disease.J Pediatric Infect Dis Soc. 2018 May 9;7(suppl_1):S6-S11. doi: 10.1093/jpids/piy007. J Pediatric Infect Dis Soc. 2018. PMID: 29746674 Free PMC article. Review.
-
Recent advances in chronic granulomatous disease.Genes Dis. 2019 Jul 27;7(1):84-92. doi: 10.1016/j.gendis.2019.07.010. eCollection 2020 Mar. Genes Dis. 2019. PMID: 32181279 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous